YWYing Wu

Ying Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Wu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Chun-Lian Jin

    China Medical University, Shenyang, P.R. China

    1 shared publication
  • Da-Wen Zhou

    Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, P.R. China

    1 shared publication
  • Fanyi Zeng

    Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, PR China

    1 shared publication
  • Hongguang Zhu

    Department of Pathology, Fudan University Shanghai Medical College, Yixueyuan Road 138, Shanghai, China

    1 shared publication
  • Jian Li

    Department of Healthcare, Philips Research Asia - Shanghai, No 10, Lane 888, Tian Lin Road, Shanghai 200233, PR China

    1 shared publication
  • Jing-Bin Yan

    Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors

    by Shuyang Wang, Lei Wang, Tengfang Zhu, Xue Gao, Jian Li, Ying Wu, Hongguang Zhu

    Background: Laser capture microdissection (LCM) has successfully isolated pure cell populations from tissue sections and the combination of LCM with standard genomic and proteomic methods has revolutionized molecular analysis of complex tissue. However, the quantity and quality of material recovered after LCM is often still limited for analysis by using whole genomic and proteomic approaches. To procure high quality and quantity of RNA after LCM, we optimized the procedures on tissue preparations and applied the approach for cell type-specific miRNA expression profiling in colorectal tumors. Results: We found that the ethanol fixation of tissue sections for 2 hours had the maximum improvement of RNA quality (1.8 fold, p = 0.0014) and quantity (1.5 fold, p = 0.066). Overall, the quality (RNA integrity number, RIN) for the microdissected colorectal tissues was 5.2 ± 1.5 (average ± SD) for normal (n = 43), 5.7 ± 1.1 for adenomas (n = 14) and 7.2 ± 1.2 for carcinomas (n = 44). We then compared miRNA expression profiles of 18 colorectal tissues (6 normal, 6 adenomas and 6 carcinomas) between LCM selected epithelial cells versus stromal cells using Agilent miRNA microarrays. We identified 51 differentially expressed miRNAs (p <= 0.001) between these two cell types. We found that the miRNAs in the epithelial cells could differentiate adenomas from normal and carcinomas. However, the miRNAs in the stromal and mixed cells could not separate adenomas from normal tissues. Finally, we applied quantitative RT-PCR to cross-verify the expression patterns of 7 different miRNAs using 8 LCM-selected epithelial cells and found the excellent correlation of the fold changes between the two platforms (R = 0.996). Conclusions: Our study demonstrates the feasibility and potential power of discovering cell type-specific miRNA biomarkers in complex tissue using combination of LCM with genome-wide miRNA analysis.


  • Array-MLPA: comprehensive detection of deletions and duplications and its application to DMD patients

    by Fanyi Zeng, Zhao-Rui Ren, Shang-Zhi Huang, Margot Kalf, Monique Mommersteeg, Maarten Smit, Stefan White, Chun-Lian Jin, Miao Xu, Da-Wen Zhou, et al.

    Multiplex ligation‐dependent probe amplification (MLPA) is widely used to screen genes of interest for deletions and duplications. Since MLPA is usually based on size‐separation of the amplification products, the maximum number of target sequences that can be screened in parallel is usually limited to ∼40. We report the design of a robust array‐based MLPA format that uses amplification products of essentially uniform size (100–120 bp) and distinguishes between them by virtue of incorporated tag sequences. We were thus able to increase probe complexity to 124, with very uniform product yields and signals that have a low coefficient of variance. The assay designed was used to screen the largest set studied so far (249 patients) of unrelated Duchenne muscular dystrophy (DMD) cases from the Chinese population. In a blind study we correctly assigned 98% of the genotypes and detected rearrangements in 181 cases (73%); i.e., 163 deletions (65%), 13 duplications (5%), and five complex rearrangements (2%). Although this value is significantly higher for Chinese patients than previously reported, it is similar to that found for other populations. The location of the rearrangements (76% in the major deletion hotspot) is also in agreement with other findings. The 96‐well flow‐through microarray system used in this research provides high‐throughput and speed; hybridization can be completed in 5 to 30 minutes. Since array processing and data analysis are fully automated, array‐MLPA should be easy to implement in a standard diagnostic laboratory. The universal array can be used to analyze any tag‐modified MLPA probe set. Hum Mutat 29(1), 190–197, 2008.